The utility of ICER reports for private payer budgeting: Budget impact analyses

  • Print
  • Connect
  • Email
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
By Tia Goss Sawhney, Bruce S. Pyenson, Eric Buzby | 17 January 2019

The Institute for Clinical and Economic Review (ICER) publishes value assessments for new drugs that include a “potential budget impact.” ICER budget impact analyses may provide negotiating points that some payers can use when contracting for certain drugs. This report identifies several disconnects between ICER’s work and its potential use by private payers to analyze the impact of new drugs on their budgets.

This report was commissioned by The Pharmaceutical Research and Manufacturers of America (PhRMA).